Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

Aithal, Guruprasad P., Thomas, James A., Kaye, Philip V., Lawson, Adam, Ryder, Stephen D., Spendlove, Ian, Austin, Andrew S., Freeman, Jan G. +2 more·2008·Gastroenterology

DOI 10.1053/j.gastro.2008.06.047

Cited by (719)

Items 201–300 of 719

Therapeutic Trials in Nonalcoholic Steatohepatitis
Vlad Ratziu, Stephen Hugh Caldwell, Brent A. Neuschwander‐Tetri · 2010 · Hepatology
Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
Paul Peter Manka, Amos Cornelius Zeller, Wing‐Kin Syn · 2019 · Drugs
Antifibrotic Therapies in the Liver
Detlef Schuppan, Wajahat Zafar Mehal · 2015 · Seminars in Liver Disease
Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies
Dunya Tomic, William W. Kemp, Stuart Keith Roberts · 2018 · European Journal of Gastroenterology & Hepatology
Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease
Hyejin Yoon · 2014 · World Journal of Hepatology
Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)
Rosa Lombardi, Simona Onali, Douglas Thorburn, Brian Ritchie Davidson, Kurinchi Selvan Gurusamy, Emmanuel A. Tsochatzis · 2017 · Cochrane Database of Systematic Reviews
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review
Ian Blazina, Shelley Selph · 2019 · Systematic Reviews
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
D Shyangdan, Christine Clar, Nazim Ghouri, R Henderson, Tul Maya Gurung, David Preiss, Naveed A. Sattar, Abigail Fraser, Norman R Waugh · 2011 · Health Technology Assessment
A critical review of endpoints for non-cirrhotic NASH therapeutic trials
Ratziu, Vlad · 2018 · Journal of Hepatology
Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease
Narendra Singh Choudhary, Naveen Kumar, Ajay Kumar. Duseja · 2019 · Journal of Clinical and Experimental Hepatology
Experimental liver models: From cell culture techniques to microfluidic organs‐on‐chip
Michela Anna Polidoro, Erika Ferrari, Simona Marzorati, Ana Lleò, Marco Rasponi · 2021 · Liver International
Erlotinib loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential
Parijat Pandey, Kamal Dua, Harish Dureja · 2019 · International Journal of Biological Macromolecules
The current role of thiazolidinediones in diabetes management
Christos V. Rizos, Anastazia A. Kei, Moses Elisaf · 2016 · Archives of Toxicology
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Idoia Genua, Kenneth J. Cusi · 2024 · Diabetes Spectrum
Mitochondria and Redox Signaling in Steatohepatitis
E. Matthew Morris, R. Scott Rector, John P. Thyfault, Jamal A. Ibdah · 2010 · Antioxidants and Redox Signaling
Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial
Elena Sofer, Mona Boaz, Zipora Matas, Margarita Mashavi, Marina Shargorodsky · 2011 · Metabolism
Novel Anti-fibrotic Therapies
Benita L. McVicker, Robert G. Bennett · 2017 · Frontiers in Pharmacology
Development and prognosis of hepatocellular carcinoma in patients with diabetes
Takuma Nakatsuka, Ryosuke Tateishi · 2022 · Clinical and Molecular Hepatology
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
Ng, Cheng Han, Xiao, Jieling, Lim, Wen Hui, Chin, Yip Han, Yong, Jie Ning, Tan, Darren Jun Hao, Tay, Phoebe, Syn, Nicholas, Foo, Roger, Chan, Mark et al. · 2022 · Hepatology
Nonalcoholic Fatty Liver Disease and the Coronary Artery Disease
Sombat Treeprasertsuk, Francisco Alejandro López-Jiménez, Keith D. Lindor · 2010 · Digestive Diseases and Sciences
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
Alejandro Campos-Murguía, Astrid Ruiz‐Margáin, José Alberto González-Regueiro, Ricardo Ulises Macías‐Rodríguez · 2020 · World Journal of Gastroenterology
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Kenneth J. Cusi · 2020 · Diabetes Care
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026
Mandeep Singh Bajaj, Rozalina G. McCoy, Kirthikaa Balapattabi, Raveendhara R. Bannuru, Natalie J. Bellini, Allison K. Bennett, Elizabeth Ann Beverly, Kathaleen Briggs Early, Sathyavathi ChallaSivaKanaka, Justin Basile Echouffo-Tcheugui et al. · 2025 · Diabetes Care
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Newaz Hossain, Pushpjeet Kanwar, Smruti Ranjan Mohanty · 2016 · Gastroenterology Research and Practice
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, Miwa Kawanaka, Hideki Fujii, Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuichiro Eguchi, Masafumi Ono et al. · 2020 · International Journal of Molecular Sciences
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis
Maryam Mahjoubin‐Tehran, Antonio De Vincentis, Dimitri P. Mikhailidis, Stephen Lawrence Atkin, Christos Socrates Mantzoros, Tannaz Jamialahmadi, Amirhossein Sahebkar · 2020 · Molecular Metabolism
Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease
Emad A. Rakha, Louise M. Adamson, Emily Bell, Keith R Neal, Stephen D. Ryder, Philip Kaye, Guruprasad Padur Aithal · 2010 · Journal of Clinical Pathology
Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis
Thomas Greuter, Harmeet Malhi, Gregory James Gores, Vijay H. Shah · 2017 · JCI Insight
Controversies in the Diagnosis and Management of NAFLD and NASH.
Mary Eugenia Rinella, Rohit Seth Loomba, Stephen Hugh Caldwell, Kris V. Kowdley, Michael Charlton, Brent A. Tetri, Stephen A. Harrison · 2014 · PubMed Central
Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review
Juan Pablo Arab · 2014 · World Journal of Gastroenterology
First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients
2021
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Joeri Lambrecht, Leo A. van Grunsven, Frank Tacke · 2020 · Expert Opinion on Pharmacotherapy
Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease
Ignazio Grattagliano, Liliana P. Montezinho, Paulo Jorge Oliveira, Gema Frühbeck, Javier Gómez‐Ambrosi, Fabrizio Montecucco, Federico Carbone, Mariusz Roman Wieckowski, David Q.‐H. Wang, Piero Portincasa · 2018 · Biochemical Pharmacology
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis
Detlef Schuppan, Mark D. Gorrell, Thomas Klein, Michael Mark, Nezam H. Afdhal · 2009 · Liver International
Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?
Amedeo Lonardo, Stefano Bellentani, Vlad Ratziu, Paola Loria · 2011 · Expert Review of Gastroenterology & Hepatology
NAFLD/NASH in patients with type 2 diabetes and related treatment options
Maria Grazia Radaelli, Federico Martucci, Silvia Perra, Silvia Accornero, Giovanna Castoldi, Guido Lattuada, G. Manzoni, Gianluca Perseghin · 2017 · Journal of Endocrinological Investigation
A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France
Vlad Ratziu, Jean–François Cadranel, Lawrence Serfaty, Jacques Denis, Christophe Renou, Patrick Delasalle, Carole Bernhardt, Gabriel Perlemuter · 2012 · Journal of Hepatology
Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome
Robert S. Rahimi, Carmen E. Landaverde · 2013 · Nutrition in Clinical Practice
Phase 3 drug pipelines in the treatment of non‐alcoholic steatohepatitis
Yoshio Sumida, Takeshi Okanoue, Atsushi Nakajima, Japan Study Group of NAFLD (JSG‐NAFLD) · 2019 · Hepatology Research
Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD)
Ratree Sawangjit, Bunchai Chongmelaxme, Pochamana Phisalprapa, Surasak Saokaew, Ammarin Thakkinstian, Kris V. Kowdley, Nathorn Chaiyakunapruk · 2016 · Medicine
Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross‐sectional study using transient elastography
D. J. Harman, Stephen D. Ryder, Martin Wynn James, Emilie Wilkes, Tim R Card, Guruprasad Padur Aithal, Indra Neil Guha · 2017 · Alimentary Pharmacology & Therapeutics
Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease
Qiongyao He, Wu He, Hui Dong, Yujin Guo, Gang Yuan, Xiaoli Shi, Dingkun Wang, Fuer Lu · 2024 · Cell Communication and Signaling
Insights into the Role of PPARβ/δ in NAFLD
Jiapeng Chen, Alexandra Montagner, Nguan Soon Tan, Walter Wahli · 2018 · International Journal of Molecular Sciences
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
Jeffrey Thomas Budd, Kenneth J. Cusi · 2020 · The American Journal of Medicine
Pharmacological agents for NASH
Vlad Ratziu · 2013 · Nature Reviews Gastroenterology & Hepatology
Causes of and Prevention Strategies for Hepatocellular Carcinoma
Giuseppe Cabibbo, Marcello Fabio Maida, Chiara Genco, Michela Antonucci, Calogero Cammà · 2012 · Seminars in Oncology
The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial
Mohsen Razavizade, Raika Jamali, Abbas Arj, Sayyed Mohammad Matini, Alireza Moraveji, Effat Taherkhani · 2013 · Hepatitis Monthly
Thiazolidinediones and the liver in humans
Hannele Yki‐Järvinen · 2009 · Current Opinion in Lipidology
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Jeffrey Thomas Budd, Kenneth J. Cusi · 2020 · Current Diabetes Reports
The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes
Carrie R. Wong, Joseph K. Lim · 2018 · Clinical Liver Disease
Hepatic steatosis and Type 2 diabetes: current and future treatment considerations
John W. Richard, Ildiko Lingvay · 2011 · Expert Review of Cardiovascular Therapy
Non‐alcoholic fatty liver disease
Ana C. Tuyama, Charissa Chang · 2012 · Journal of Diabetes
Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis
Rahul Sao, Wilbert S. Aronow · 2017 · Archives of Medical Science
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Paola Portillo-Sánchez, Kenneth J. Cusi · 2016 · Clinical Diabetes and Endocrinology
Similarities and Differences in the Pathogenesis of Alcoholic and Nonalcoholic Steatohepatitis
Wing‐Kin Syn, Vanessa S. Teaberry, Steve S. Choi, Anna Mae Diehl · 2009 · Seminars in Liver Disease
Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo
Shaoyun Wang, Amrita Kamat, Pablo E. Pérgola, Anita Swamy, Fermin O. Tio, Kenneth J. Cusi · 2011 · Metabolism
Thiazolidinediones for nonalcoholic steatohepatitis
Lingling He, Xiaoli Liu, Lijia Wang, Zhiyun Yang · 2016 · Medicine
A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
Stuart McPherson, Nina Wilkinson, DINA G. TINIAKOS, Jennifer S. Wilkinson, Alastair D. Burt, Elaine McColl, Deborah D. Stocken, Nick D. Steen, Jane A. Barnes, Nicola Goudie et al. · 2017 · PLoS ONE
Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome
Warshauer, Jeremy T., Lopez, Ximena, Gordillo, Ruth, Hicks, Jessica, Holland, William L., Anuwe, Estelle, Blankfard, Martin B., Scherer, Philipp E., Lingvay, Ildiko · 2015 · Diabetes/Metabolism Research and Reviews
Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials
Zeyu Wang, Du Huiqing, Ying Zhao, Yadi Ren, Cuihua Ma, Hongyu Chen, Man Li, Jiageng Tian, Caihong Xue, Guangfeng Long et al. · 2023 · Frontiers in Endocrinology
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease
Jacob J. Gries, Jeffrey Victor Lazarus, Paul Brennan, Mohammad Shadab Siddiqui, Giovanni Targher, Chim Choy Lang, Salim S. Virani, Carl J. Lavie, Scott D. Isaacs, Juan Pablo Arab et al. · 2024 · The Lancet. Gastroenterology & hepatology
The safety of thiazolidinediones
Keith G. Tolman · 2011 · Expert Opinion on Drug Safety
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Michael P. Cooreman, Luisa Vonghia, Sven Francque · 2024 · Diabetes Research and Clinical Practice
Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review
Everton Cazzo, José Carlos Pareja, Élinton Adami Chaim · 2017 · Sao Paulo Medical Journal
Crosstalk between PPARs and gut microbiota in NAFLD
Liwei Wu, Jingjing Li, Jiao Feng, Jie Ji, Qiang Yu, Yan Li, Yuanyuan Zheng, Weiqi Dai, Jianye Wu, Chuanyong Guo · 2021 · Biomedicine & Pharmacotherapy
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Приходько Вероника Александровна, Natalia N. Bezborodkina, Sergey V. Okovityi · 2022 · Biomedicines
Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Eugene Chang, Cheol‐Young Park, Sung Woo Park · 2013 · Journal of Diabetes Investigation
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
Matthew James Armstrong, Darren Barton, Piers Gaunt, Diana Hull, Kathy Guo, Deborah D. Stocken, Stephen C. L. Gough, Jeremy Tomlinson, Rachel Mary Brown, Stefan G. Hübscher et al. · 2013 · BMJ Open
NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
Stephen Hugh Caldwell · 2017 · Clinical and Molecular Hepatology
Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Matteo Tacelli, Ciro Celsa, Bianca Magro, Aurora Giannetti, Grazia Pennisi, Federica Spatola, Salvatore Petta · 2018 · Pharmaceuticals
A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
Kenneth J. Cusi · 2020 · Liver International
A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-β signaling in hepatic stellate cells
Nanaho Kasahara, Yukiko Imi, Reina Amano, Masakazu Shinohara, Kumiko Okada, Yusei Hosokawa, Makoto Imamori, Chiaki Tomimoto, Jun Kunisawa, Shigenobu Kishino et al. · 2023 · Scientific Reports
Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus
Wojciech Konrad Karcz, Daniel R. Krawczykowski, Simon Kuesters, Goran Marjanović, Birte Kulemann, H Gröbe, Iwona Karcz-Socha, U. T. Hopt, Waleed Bukhari, Jodok Matthias Grueneberger · 2010 · Journal of Obesity
Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning?
Bülent Baran · 2014 · World Journal of Gastroenterology
Antifibrotics in chronic liver disease: tractable targets and translational challenges
Prakash Ramachandran, Neil Cowan Henderson · 2016 · The Lancet. Gastroenterology & hepatology
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis
Suzanne E. Mahady, Germaine Wong, Jonathan C. Craig, Jacob George · 2012 · Hepatology
Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement
Jérôme Boursier, Rodolphe Anty, Claire Carette, Bertrand Cariou, Laurent Castéra, Cyrielle Caussy, Hélène Fontaine, Armand Garioud, Pierre Gourdy, Bruno Guerci et al. · 2021 · Diabetes & Metabolism
Novel treatment modalities for nonalcoholic steatohepatitis
Sanjaya Kumar Satapathy, Arun Jayant Sanyal · 2010 · Trends in Endocrinology and Metabolism
Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)
Iliana Doycheva, Rohit Seth Loomba · 2014 · Advances in Therapy
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim · 2020 · Clinical and Molecular Hepatology
The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?
Paola Dongiovanni, Raffaela Rametta, Marica Meroni, Luca V. C. Valenti · 2015 · Expert Review of Gastroenterology & Hepatology
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
Won Sohn, Young‐Sun Lee, Soon Sun Kim, Jung Hee Kim, Young‐Joo Jin, Gi‐Ae Kim, Pil Soo Sung, Jeong‐Ju Yoo, Young Woon Chang, Eun Joo Lee et al. · 2025 · Clinical and Molecular Hepatology
Current and future treatment options in non-alcoholic steatohepatitis (NASH)
Nikolaos Lazaridis, Emmanuel A. Tsochatzis · 2017 · Expert Review of Gastroenterology & Hepatology
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
Laura Iogna Prat, Emmanuel A. Tsochatzis · 2018 · HORMONES
Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease
Wah‐Kheong Chan, Soek-Siam Tan, Siew-Pheng Chan, Yeong Yeh Lee, Hoi‐Poh Tee, Sanjiv Mahadeva, Khean‐Lee Goh, Anis Safura Ramli, Feisul Idzwan Mustapha, Nik Ritza Kosai et al. · 2022 · Journal of Gastroenterology and Hepatology
The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Yasser Mahrous Fouad, Gamal Esmat, Reda Elwakil, Serag Zakaria, Ayman Yosry, Imam A. Waked, Maissa El-Razky, Wahid H. Doss, Magdy El‐Serafy, Ebraheem Mostafa et al. · 2022 · Saudi Journal of Gastroenterology
Thyroid hormone analogues and derivatives: Actions in fatty liver
Maria Coppola · 2014 · World Journal of Hepatology
A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
Surosree Ganguli, Peter Deleeuw, Sanjaya Kumar Satapathy · 2019 · Hepatic Medicine Evidence and Research
Broad Spectrum of Hepatocyte Inclusions in Humans, Animals, and Experimental Models
Pavel Strnad, Renwar Nuraldeen, Nurdan Güldiken, Daniel Hartmann, Vineet Mahajan, Helmut Denk, Johannes Haybaeck · 2013 · Comprehensive physiology
Treatment regimens for non-alcoholic fatty liver disease
Brian P Lam, Zobair M. Younossi · 2009 · Annals of Hepatology
Review of Treatment Options for Nonalcoholic Fatty Liver Disease
Richele Corrado, Dawn McDowell Torres, Stephen A. Harrison · 2013 · Medical Clinics of North America
Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36‐month clinical trial
Paola Portillo-Sánchez, Fernando Bril, Romina Lomonaco, Diana Barb, Beverly Orsak, Jan Bruder, Kenneth J. Cusi · 2018 · Journal of Diabetes
Consenso mexicano de la enfermedad por hígado graso no alcohólico
Raúl Bernal-Reyes, Graciela Castro‐Narro, René Malé-Velázquez, Ramón Carmona-Sánchez, M.S. González-Huezo, Ignacio García-Juárez, Norberto Carlos Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia et al. · 2019 · Revista de Gastroenterología de México
Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect
Rajiv Prakash Heda, Masahiko Yazawa, Michelle Y. Shi, Madhu C. Bhaskaran, Fuad Zain Aloor, Paul Joseph Thuluvath, Sanjaya Kumar Satapathy · 2021 · World Journal of Gastroenterology
Changing clinical management of NAFLD in Asia
Takuma Nakatsuka, Ryosuke Tateishi, Kazuhiko Koike · 2021 · Liver International
Treatment of Non-Alcoholic Fatty Liver Disease
Jessica Katharine Dyson, Chris Day · 2014 · Digestive Diseases
Crosstalk between angiogenesis, cytokeratin-18, and insulinresistance in the progression of non-alcoholic steatohepatitis
Mitsuteru Kitade, Hitoshi Yoshiji, Ryuichi Noguchi, Yasuhide Ikenaka, Kosuke Kaji, Yusaku Shirai, Masaharu Yamazaki, Masahito Uemura, Junichi Yamao, Masao Fujimoto et al. · 2009 · World Journal of Gastroenterology
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes ( <scp>EDICT</scp> )
Lavynenko, Olga, Abdul‐Ghani, Muhammad, Alatrach, Mariam, Puckett, Curtiss, Adams, John, Abdelgani, Siham, Alkhouri, Naim, Triplitt, Curtis, Clarke, Geoffrey D., Vasquez, Juan A. et al. · 2022 · Diabetes, Obesity and Metabolism
Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review
Sarah Lindback, Charles C. Gabbert, B. Lamar Johnson, Emmanuil Smorodinsky, Claude B. Sirlin, Natalie C. Garcia, Perrie E. Pardee, Kristin D. Kistler, Jeffrey B. Schwimmer · 2010 · Advances in Pediatrics
Non‐alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies
Mária Pallayová, Shahrad Taheri · 2014 · Clinical Obesity